Our Core

We aspire to make a lasting impact for patients with cardiac diseases

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

Management Team

Claudia Ulbrich
Claudia Ulbrich
MD
CEO & Co-Founder
Thomas Thum
Prof. Thomas Thum
MD, PhD
CSO & Founder
Rahul Agrawal
Rahul Agrawal
MD
CMO

Board

Claus Andersson
Claus Andersson
PhD
Jan van den Bossche
Jan Van den Bossche
Simone Botti
Simone Botti
PhD
Martin Crook
Martin Crook
PhD
Ulrich Granzer
Ulrich Granzer
PhD
Markus Hosang
Markus Hosang
PhD
Karin Kleinhaus
Karin Kleinhans
PhD

Scientific Advisory Board

Prof. Scott Solomon
MD
Arthur A. Levin
PhD
Prof. Javed Butler
MD
Prof. Faiez Zannad
MD, PhD
Prof. Douglas L. Mann
MD
David Crandall
PhD

Investors

Cardior is supported by a range of prestigious life science investors.

Partners

We have established successful relationships with renowned academic partners and are always looking for new collaboration opportunities to further advance our innovative therapy approach.

Claudia Ulbrich

MD
Claudia Ulbrich
CEO & Co-Founder

Claudia Ulbrich

MD

Dr. Claudia Ulbrich, Co-Founder and CEO at Cardior, is an MD and health economist (ebs) by training with more than 25 years of management expertise in private and public biotech companies. Claudia is an integrative, experienced leader guiding international, cross-functional teams based on a broad range of experience in M&A, transaction management and consulting. She brings a strong network in venture capital, academia, and industry. Claudia combines a high level of commercial competence with a sound knowledge of medical affairs and drug development all along the valuation chain. With her excellent abilities in financing, transactions of up to 2bn EUR and strategy she is responsible for general management including P&L, corporate development, and investor relations. In 1998, Claudia founded her first biotech company, LipoNova AG (IPO in 2006), after which she served as Co-Founder, executive advisor, and interim manager of several international biotech companies, such as uniQure N.V., InoCard GmbH and t-cell Europe GmbH. Having worked as Senior Advisor at PricewaterhouseCoopers she started her own consulting business in 2008. Claudia holds several Board positions in relevant public and trade organizations.

Prof. Thomas Thum

MD, PhD
Thomas Thum
CSO & Founder

Prof. Thomas Thum

MD, PhD

Prof. Dr. Dr. med. Thomas Thum, Founder and CSO of Cardior, is a key opinion leader in cardiac diseases and the development of RNA-based therapeutics and has received numerous awards for his work. Thomas is a member of the editorial boards of the world’s most prestigious journals for cardiovascular research and an executive member of national and international research committees in the cardiovascular field. Since 2009, Thomas is Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hanover Medical School (MHH) and visiting professor at the National Heart and Lung Institute at Imperial College London since 2013. Most recently he was appointed as Director of the neighboring Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hanover, Germany. He has authored over 400 scientific publications in renowned and field-leading journals and has filed over 40 patents, nine of which have been successfully licensed to pharma companies and are currently in Phase 1/2 clinical development.

Rahul Agrawal

MD
Rahul Agrawal
CMO

Rahul Agrawal

MD

Dr. Rahul Agrawal is a board-certified cardiologist and emergency medicine physician with more than 20 years of industry experience, including global and senior medical positions focused on cardiac indications at Bayer and AstraZeneca. Rahul has led several clinical development programs in the cardiovascular, respiratory, metabolic, renal, and rare diseases space through to product approval with the FDA, EMA, PMDA, and CFDA. During his tenure, he developed global strategies to achieve the business and development goals for several cardiovascular therapeutics, in addition to leading the successful closeout of several of AstraZeneca’s global Phase 3 trials. Most recently he held the position of VP and Global Medicines Leader, Cardiovascular at AstraZeneca. Prior to AstraZeneca, Rahul was Global Director, Medical Affairs and Clinical, Global Launch Team, Pulmonary Hypertension at Bayer HealthCare. In this role, he led the marketing and branding efforts for the company’s pulmonary hypertension portfolio. Rahul holds a Doctor of Medicine from the Charité University Hospital, Berlin where he worked as a physician and scientist at the Department of Cardiology and Pulmonology. He holds an MBA from Buckinghamshire New University, United Kingdom.

Claus Andersson

PhD
Claus Andersson

Claus Andersson

PhD

Claus Andersson is a General Partner at Sunstone Life Science Ventures, where he has been part of the team since its inception, focusing on oncology, cardiology, and nucleotide modalities. So far, Claus has been active with more than 19 companies in which he has held either chairing positions or board memberships to share his experience from the last 18 years of working with entrepreneurs, co-investors, and consultants in the life sciences. Claus has extensive experience in strategy execution and technology development from various parts of the life science ecosystem – both as an entrepreneur, venture capitalist, scientist, and corporate manager. Claus holds a master’s degree in Civil Chemical Engineering from the Technical University of Denmark (DTU) and a PhD in Mathematical Statistics from the University of Copenhagen and the Humboldt University in Berlin.

Jan Van den Bossche

Jan van den Bossche

Jan Van den Bossche

Jan Van den Bossche is a Partner at Fund+, a healthcare-focused venture capital firm. Before joining Fund+, Jan served on the investor relations team at the Dutch life sciences and materials sciences company DSM, Geleen, The Netherlands. Previously, he worked for more than 12 years as a biotech analyst at Petercam, where he was involved in several public and private transactions of Belgian and Dutch biotech companies, including ThromoboGenics, Tigenix, UCB, AMT (Uniqure), IBA, and MDxHealth. Jan holds a Bachelor of Economics and a master’s degree in Business Economics from the Katholieke Universiteit Leuven, Belgium and completed the CFA (Chartered Financial Analyst) program at the CFA Institute.

Simone Botti

PhD
Simone Botti

Simone Botti

PhD

Simone Botti is a Junior Partner in the Healthcare team at INKEF. Simone brings with him more than 15 years of experience across venture capital and start-up creation and leadership. Before joining INKEF Simone was CEO of Metabomed, an early-stage cancer metabolism company he co-founded while he was Head of the Israel Bioincubator Fund at M Ventures, which he joined in 2011. Simone developed his company-building experience while at M Ventures, where he established a number of early-stage companies. During that time Simone also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Previously, he was Vice President, Business Development at RAD Biomed Accelerator, one of Israel’s leading life science incubators. Simone did his PhD in Structural Biology and Neurobiology at the Weizmann Institute of Science, where he received the “Dov Elad” prize in Structural Biology.

Martin Crook

PhD
Martin Crook

Martin Crook

PhD

Martin Crook, PhD, serves as Executive Director, Business Development, Head of Oncology Search & Evaluation at Bristol Myers Squibb where he leads global scouting and diligence activities for therapeutic opportunities in oncology. Prior to joining BMS, Martin led drug discovery teams at Merck Research Laboratories to discover and develop novel pharmaceuticals for the treatment of cardiovascular disease. In 2012, Martin joined Daiichi Sankyo to source business development opportunities in cardiometabolic disease. Martin received his B.Sc. Hons. from Lancaster University in 1995, a M.Sc. in Immunology and Oncology from University of Birmingham in 1996 and his PhD, in cardiovascular disease, from the University of Bristol in 2000. Martin then went on to receive his postdoctoral training in Dr. Elizabeth Nabel’s Vascular Biology Branch of the National Heart Lung and Blood Institute (NIH) in Bethesda, Maryland.

Ulrich Granzer

PhD
Ulrich Granzer

Ulrich Granzer

PhD

Ulrich Granzer, PhD, is the founder and owner of Granzer Regulatory Consulting & Services and has more than 25 years of experience in drug development and regulatory affairs. He has held senior management positions at Glaxo as Director of Regulatory Affairs and was a member of Glaxo Wellcome’s Global Regulatory Board. At BASF Pharma, Ulrich served as Vice President of Global Regulatory Centers, assuming global responsibility for Regulatory Affairs, Drug Safety, and GXP in drug development. He was responsible for the development of small molecules as well as several biological compounds in the indications of obesity, stroke, septic shock, and rheumatoid arthritis at Knoll. He was instrumental to the program for the first fully human anti-TNF antibody, now marketed as Humira. Before starting his own consultancy in 2002, Ulrich joined Bayer as Vice President of Global Regulatory Affairs, whose responsibility extended over all regulatory aspects of development and submission projects. He received his graduate degree from Philipps University of Marburg and a doctorate degree from Eberhard Karls Universität Tübingen.

Markus Hosang

PhD
Markus Hosang

Markus Hosang

PhD

Markus Hosang, PhD, is a General Partner and Managing Director at BioMedPartners in Basel. He serves on the boards of Unitectra AG, Aleva Neurotherapeutics, Anergis, Hookipa Biotech, and Imevax. Earlier in his career, Markus was a venture partner at MPM Capital, where he managed their European office in Munich and served on the boards of several of their European portfolio companies including Omrix Pharmaceuticals, Kourion, IDEA and Atugen. Before that, Markus was at Roche in Basel for nearly 20 years, where he held several senior management positions. He obtained his PhD in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington Medical School in Seattle where he published numerous articles in peer-reviewed journals.

Karin Kleinhans

PhD
Karin Kleinhaus

Karin Kleinhans

PhD

Karin Kleinhans, PhD, is a Partner at LSP and her investment focus primarily is on private companies. Prior to joining LSP, Karin was an associate in an international patent law firm where she was involved in all aspects of the patent life cycle for international clients in the biotech industry. She has experience in clinical trials and regulatory affairs within pharmaceutical drug development and has conducted research at the Max-Planck Department for Stem Cell Aging and the Institute of Molecular Medicine at the University Ulm. Her research focused on the basic mechanisms resulting in cellular and organismal aging, DNA damage and disease, which led to a number of scientific publications and book chapters in renowned journals. Karin received her PhD from the International Graduate School in Molecular Medicine in Ulm. She was awarded her bachelor’s and master’s degree in Molecular Medicine where she combined medical studies with scientific research training.

Prof. Scott Solomon

MD

Prof. Scott Solomon

MD

Prof. Scott D. Solomon, MD, is The Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School, and Senior Physician at Brigham and Women’s Hospital. He directs the Clinical Trials Outcomes Center and the Cardiac Imaging Core Laboratory at Brigham and Women’s Hospital. Scott has pioneered the use of cardiac imaging in cardiovascular drug and device development and use of imaging in clinical trials and has played a leading role in many international clinical trials in heart failure, hypertension, and myocardial infarction. He led the first positive Phase II trial in HFpEF, and his work led to the first FDA indication for a therapy for heart failure with ejection fraction > 40%. Scott received his A.B. from Williams College and his MD from Harvard Medical School and has authored more than 800 peer-reviewed articles, reviews, and editorials, two textbooks of cardiac imaging. He serves as editor for Braunwald’s Heart Disease, the premiere textbook of cardiovascular medicine.

Arthur A. Levin

PhD

Arthur A. Levin

PhD

Arthur A. Levin, PhD, is Avidity Bioscience’s Executive Vice President of Research and Development with nearly 30 years of experience in the pharmaceutical industry. He has been involved in the development of more than 20 oligonucleotide therapeutics, including both approved antisense drugs. Prior to joining Avidity, Arthur ran research and development at miRagen Therapeutics and was Chief Development Officer at Santaris Pharma where he led the efforts on the first microRNA-targeting therapeutic currently in Phase 2 clinical trials. Before joining Santaris Pharma, he consulted for leading biotechnology and pharmaceutical companies, conducting research and development in RNA-based therapies. Prior to consulting, Arthur was Senior Vice President of Development at Isis Pharmaceuticals. He holds a PhD in Toxicology from the University of Rochester School of Medicine and Dentistry, New York and a B.Sc. in Biology from Muhlenberg College. He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. In addition, he authored more than 70 papers and book chapters.

Prof. Javed Butler

MD

Prof. Javed Butler

MD

Prof. Javed Butler is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center. Prior to joining the University of Mississippi, he was Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University. Javed serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America as well as editorial boards of peer-reviewed cardiovascular journals. He received his medical degree from the Aga Khan University and completed residency training at Yale University. Javed holds a Master of Public Health degree from Harvard University and MBA from Emory University. He has authored more than 800 peer-reviewed publications and was rewarded with the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.

Prof. Faiez Zannad

MD, PhD

Prof. Faiez Zannad

MD, PhD

Prof. Faiez Zannad, MD, Cardiologist and heart failure specialist, PhD in Clinical Pharmacology, FESC is Emeritus Professor of Therapeutics at the University of Lorraine and former Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux”, Nancy, France. Faiez has led two EU FP7 grant programs and is part of oversight committees in major clinical trials and made significant contributions to evidence-based heart failure therapy, as well as in major comorbid diseases. He served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. Faiez is organizing the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think-tank gathering dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Middle East and Asia. As of June 2021, Faiez has published more than 940 peer-reviewed papers. In 2014, he was awarded the European Society of Hypertension Paul Milliez Award and in 2017 the Lifetime Achievement Award from the ESC Heart Failure Association.

Prof. Douglas L. Mann

MD

Prof. Douglas L. Mann

MD

Prof. Dr. Douglas L. Mann is the Lewin Distinguished Professor of Cardiovascular Disease and Professor of Cell Biology and Physiology at the Washington University School of Medicine in St. Louis. Douglas’ primary research interest has been the molecular and cellular basis of heart failure. He is Editor-in-Chief of JACC: Basic to Translational Science and is on the Editorial Board for a number of other leading cardiovascular journals. Additionally, he is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, the American Association for the Advancement of Science, and the Association of University Cardiologists, as well as a member and past-president of the Heart Failure Society of America. Douglas received his medical degree from Temple University School of Medicine in Philadelphia and completed fellowships in clinical cardiology at the University of California San Diego, and Massachusetts General Hospital in Boston. He is the author of numerous peer-reviewed articles on the role of inflammatory mediators in cardiac remodeling and myocardial recovery.

David Crandall

PhD

David Crandall

PhD

David Crandall, PhD, brings both scientific and executive R&D leadership experience from 30 years in the pharmaceutical industry. David held a leadership position at Johnson & Johnson, where he was responsible for the executive management of the heart failure portfolio, which included programs from preclinical discovery through early clinical development. He was instrumental in developing a hybrid research model blending internal expertise with external opportunities from academia and biotech to successfully advance programs into early clinical development. As a component of this position, David was a key corporate representative in discussions with potential partners and equity analysts. Prior to joining Johnson & Johnson, Dr. Crandall held positions of increasing responsibility in pharmaceutical R&D at Bristol-Myers Squibb and Wyeth (Pfizer) research. David received his PhD in Physiology from Iowa State University and was an NIH postdoctoral fellow in Endocrinology/Medicine at Emory University. He is the author of numerous peer-reviewed scientific publications, book chapters and U.S. and foreign patents, and has served on the editorial boards of key journals in the field of drug discovery.